Trials / Unknown
UnknownNCT01317888
Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
An Access Protocol for Continued Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody Radiolabeled With 1-125 for High Grade Gliomas
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- Sponsor
- Drexel University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this access protocol is to allow patients with brain tumors who had previously received 125I-MAB 425 to receive additional course(s) of 125I-MAB 425 until their brain tumor begins to grow, they develop side effects to the treatment, or their medical condition changes (e.g., you become pregnant, become infected with human immunodeficiency virus (HIV) or develop another cancer).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAB-425 radiolabeled with I-125 | MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2014-01-01
- First posted
- 2011-03-17
- Last updated
- 2011-03-17
Source: ClinicalTrials.gov record NCT01317888. Inclusion in this directory is not an endorsement.